Though 10% more patients in the SANTORINI registry achieved their lipid goal after 1 year thanks to increased use of combination therapies, the results are still "very disappointing," says one expert.
Children and adolescents with homozygous familial hypercholesterolemia could benefit from lomitapide therapy, suggests a trial, although safety concerns and upcoming novel drugs question its place.